Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults

Journal of Geriatric Oncology

Volumn 6, Issue 4, 2015, Pages 288-298

  Fega, K Rebecca ^a   Abel, Gregory A ^b   Motyckova, Gabriela ^b   Sherman, Alexander E ^c   DeAngelo, Daniel J ^b   Steensma, David P ^b   Galinsky, Ilene ^b   Wadleigh, Martha ^b   Stone, Richard M ^b   Driver, Jane A ^b,d,e  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Elderly; Geriatric; Myelodysplastic syndromes; Oncology; Prediction; Prognosis

Indexed keywords

ALBUMIN;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CAUCASIAN; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; COMORBIDITY; GERIATRIC ASSESSMENT; MYELODYSPLASTIC SYNDROMES; PROCEDURES; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK FACTOR; SELF REPORT; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SELF REPORT; SURVEYS AND QUESTIONNAIRES; SURVIVAL ANALYSIS;

EID: 84938991276     PISSN: 18794068     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgo.2015.05.003     Document Type: Article

References (40)

1. Knickman J.R., Snell E.K. The 2030 problem: caring for aging baby boomers. Health Serv Res 2002, 37(4):849-884.
2. Stauder R. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Ann Hematol 2012, 1:1.
3. Abel G.A., Koreth J. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Curr Opin Hematol 2013, 20(2):150-156.
4. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
5. Greenberg P.L., Tuechler H., Schanz J., Sanz G., Garcia-Manero G., Sole F., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120(12):2454-2465.
6. Bejar R., Stevenson K.E., Caughey B.A., Abdel-Wahab O., Steensma D.P., Galili N., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012, 30(27):3376-3382.
7. Germing U., Hildebrandt B., Pfeilstocker M., Nosslinger T., Valent P., Fonatsch C., et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005, 19(12):2223-2231.
8. Kantarjian H., O'Brien S., Ravandi F., Cortes J., Shan J., Bennett J.M., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113(6):1351-1361.
9. Schlegelberger B., Gohring G., Thol F., Heuser M. Update on cytogenetic and molecular changes in myelodysplastic syndromes. Leuk Lymphoma 2012, 53(4):525-536.
10. Fried L.P., Tangen C.M., Walston J., Newman A.B., Hirsch C., Gottdiener J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56(3):M146-M156.
11. Woods N.F., LaCroix A.Z., Gray S.L., Aragaki A., Cochrane B.B., Brunner R.L., et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc 2005, 53(8):1321-1330.
12. Hamaker M.E., Prins M.C., Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy - a systematic review. Leuk Res 2014, 38(3):275-283.
13. Tucci A., Ferrari S., Bottelli C., Borlenghi E., Drera M., Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009, 115(19):4547-4553.
14. Wildes T.M., Ruwe A.P., Fournier C., Gao F., Carson K.R., Piccirillo J.F., et al. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J geriatr oncol 2013, 4(3):227-234.
15. Klepin H.D., Geiger A.M., Tooze J.A., Kritchevsky S.B., Williamson J.D., Pardee T.S., et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013, 121(21):4287-4294.
16. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376.
17. Fayers P.M., Aaronson N.K., Bjordal K., Groenvold M., Curran D., Bottomley A., on behalf of the EORTC Quality of Life Group The EORTC QLQ-C30 scoring manual 2001, European Organisation for Research and Treatment of Cancer, Brussels. 3rd edition.
18. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
19. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96(12):3671-3674.
20. Gattermann N., Kundgen A., Kellermann L., Zeffel M., Paessens B., Germing U. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany. Eur J Haematol 2013, 91(6):473-482.
21. Hurria A., Browner I.S., Cohen H.J., Denlinger C.S., deShazo M., Extermann M., et al. Senior adult oncology. J Natl Compr Canc Netw 2012, 10(2):162-209.
22. Extermann M., Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007, 25(14):1824-1831.
23. Pal S.K., Katheria V., Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 2010, 60(2):120-132.
24. Rodin M.B., Mohile S.G. A practical approach to geriatric assessment in oncology. J Clin Oncol 2007, 25(14):1936-1944.
25. Greenberg P.L., Attar E., Bennett J.M., Bloomfield C.D., De Castro C.M., Deeg H.J., et al. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011, 9(1):30-56.
26. Decoster L., Kenis C., Van Puyvelde K., Flamaing J., Conings G., De Greve J., et al. The influence of clinical assessment (including age) and geriatric assessment on treatment decisions in older patients with cancer. J Geriatr Oncol 2013, 4(3):235-241.
27. Freyer G., Geay J.F., Touzet S., Provencal J., Weber B., Jacquin J.P., et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005, 16(11):1795-1800.
28. Caillet P., Canoui-Poitrine F., Vouriot J., Berle M., Reinald N., Krypciak S., et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011, 29(27):3636-3642.
29. Dale W., Hemmerich J., Kamm A., Posner M.C., Matthews J.B., Rothman R., et al. Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg 2014, 259(5):960-965.
30. Extermann M. Basic assessment of the older cancer patient. Curr Treat Options Oncol 2011, 12(3):276-285.
31. Klepin H.D., Geiger A.M., Tooze J.A., Kritchevsky S.B., Williamson J.D., Ellis L.R., et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc 2011, 59(10):1837-1846.
32. Deschler B., Ihorst G., Platzbecker U., Germing U., Marz E., de Figuerido M., et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013, 98(2):208-216.
33. Rothman M.D., Leo-Summers L., Gill T.M. Prognostic significance of potential frailty criteria. J Am Geriatr Soc 2008, 56(12):2211-2216.
34. Studenski S., Perera S., Patel K., Rosano C., Faulkner K., Inzitari M., et al. Gait speed and survival in older adults. JAMA 2011, 305(1):50-58.
35. Clough-Gorr K.M., Stuck A.E., Thwin S.S., Silliman R.A. Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol 2010, 28(3):380-386.
36. Hjermstad M.J., Fayers P.M., Bjordal K., Kaasa S. Using reference data on quality of life-the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3). Eur J Cancer 1998, 34(9):1381-1389.
37. Hurria A., Lichtman S.M., Gardes J., Li D., Limaye S., Patil S., et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc 2007, 55(10):1604-1608.
38. Sherman A.E., Motyckova G., Fega K.R., Deangelo D.J., Abel G.A., Steensma D., et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 2013, 37(9):998-1003.
39. Della Porta M.G., Malcovati L., Strupp C., Ambaglio I., Kuendgen A., Zipperer E., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96(3):441-449.
40. Sperr W.R., Wimazal F., Kundi M., Baumgartner C., Nosslinger T., Makrai A., et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010, 21(1):114-119.